SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: June 18, 1997
MEDIMMUNE, INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-19131
Delaware 52-1555759
(State of Incorporation) (I.R.S. Employer
Identification No.)
35 West Watkins Mill Road, Gaithersburg, MD 20878
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (301) 417-0770
No Exhibits are being filed with this report
CytoGam and RespiGam are registered trademarks of the Company.
MEDIMMUNE, INC.
Current Report on Form 8-K
ITEM 5. OTHER EVENTS
MedImmune, Inc. reported the information contained in the following press
release dated June 16, 1997:
MEDIMMUNE PRESENTS AT CAPITAL REGION TECHNOLOGY INVESTOR CONFERENCE
Marketed Products, an Extensive Pipeline and Near-term Opportunities
Gaithersburg, MD, June 16, 1997 - MedImmune, Inc. (Nasdaq:MEDI) is a
biotechnology company focused on developing and marketing products for
infectious diseases and transplantation medicine. Since commencing
operations in 1988, the Company has pursued a strategy of establishing a
commercial base using proven technologies and targeting well-understood
diseases to support longer-term product development. Total revenues in 1996
were $41 million. David M. Mott, President and Chief Operating Officer of
MedImmune, will be presenting a company update this week at the Capital
Region Technology Investor Conference in Lansdowne, VA.
MedImmune currently markets two products with its hospital-based sales
force. RespiGam (respiratory syncytial virus immune globulin intravenous
(human)) was licensed for marketing by the U.S. Food and Drug
Administration (FDA) in January 1996 for the prevention of serious
respiratory syncytial virus (RSV) disease (please see full prescribing
information). RSV is the primary cause of pneumonia and bronchiolitis in
infants. CytoGam (cytomegalovirus immune globulin intravenous (human)) is
being marketed for attenuation of cytomegalovirus (CMV) disease in kidney
transplant patients (please see full prescribing information). CMV is a
serious post-transplant infection in organ transplant recipients.
The Company has established a broad research and development portfolio with
nine proprietary products in various stages of development and clinical
testing. During the third quarter 1997, the Company expects to announce
Phase 3 clinical results of MEDI-493 which, if successfully commercialized,
could be the Company's largest product to date. MEDI-493 is a humanized
monoclonal antibody being developed for prevention of serious RSV disease
in high-risk infants and if successfully developed, would potentially
provide several advantages compared to RespiGam. The Company has a number
of vaccines in development to prevent cervical cancer, genital warts, Lyme
disease, urinary tract infections, as well as products to prevent and treat
organ transplant rejection.
The Company's facilities in Gaithersburg, MD encompass 71,000 square feet
for administration, research and development, medical and regulatory
affairs, sales and marketing, and a pilot plant. In August 1996, MedImmune
commenced construction of a $50 million, 68,000 square foot manufacturing
plant in Frederick, MD. MedImmune currently employs approximately 270
people.
This announcement may contain, in addition to historical information,
certain forward-looking statements that involve risks and uncertainties.
Such statements reflect management's current views and are based on certain
assumptions. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in the Company's filings with the U.S. Securities
and Exchange Commission.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
MEDIMMUNE, INC.
Registrant)
Date: June 18, 1997 David M. Mott
President and Chief Operating Officer
(Principal financial and
accounting officer)
